Background: Changes in pulmonary hemodynamics and cardiac function in patients with chronic obstructive pulmonary disease (COPD) traveling to altitude have not been assessed despite an increasing prevalence of the disease. Objectives: We hypothesized that pulmonary artery pressure (PAP) significantly increases and cardiac function deteriorates during exposure to hypobaric hypoxia as encountered by traveling to moderate altitude or air flight. Methods: A total of 37 patients (17 female; median age [quartiles] 66 years [60; 69] with COPD GOLD grade 2-3 [FEV 1 57% predicted (49; 71)]) living < 800 m underwent echocardiography in Zurich (490 m) and after 1 night at Davos Jakobshorn (2,590 m) in a randomized order of allocation. Results: The transtricuspid pressure gradient increased from 23 mm Hg (18; 29) to 32 mm Hg (25; 41) (p < 0.0001; Δmedian [95% CI] 7.5 [2.0; 13.0]), the right ventricular fractional area change decreased from 45% (39; 49) to 38% (33; 43) (p = 0.002), while the heart rate and systolic blood pressure increased from 70 bpm (64; 78) to 82 bpm (70; 86) (p < 0.0001) and from 133 mm Hg (123; 141) to 136 mm Hg (126; 148) (p = 0.002), respectively, and left ventricular diastolic dysfunction was more prevalent (24-54%, p = 0.02). Conclusions: This is a first study assessing changes in pulmonary hemodynamics and cardiac function in patients with COPD during a short altitude sojourn. Despite the increase in PAP and indications of change in cardiac function, the exposure was well tolerated. None of the patients had to descend to lower altitude for symptomatic altitude-related disease.
Introduction
Despite an increasing prevalence of chronic obstructive pulmonary disease (COPD) in the general population and an increasing number of people traveling to high altitude due to professional and recreational activities, only few studies on COPD patients exposed to hypobaric hypoxia at altitude report about possible implications on health and preventive strategies [1] [2] [3] [4] . The reported evidence for an altitude-associated increase in mortality rate with COPD underscores the need for research in this field [5, 6] . This is especially true for countries in which part of the population lives at higher altitude.
COPD is the most common chronic respiratory disease worldwide and is characterized by chronic airflow obstruction with airway inflammation, remodeling, and parenchymal destruction of the lung (emphysema) in some patients. Cardinal symptoms of COPD are chronic productive cough and dyspnea on exertion with limited exercise performance related to dynamic hyperinflation, exercise desaturation, and an increase in pulmonary artery pressure (PAP) [7] . Pulmonary hypertension (PH) is a complication in COPD with increasing prevalence with the severity of parenchymal lung destruction due to loss of the pulmonary capillary bed, increased hypoxic pulmonary vasoconstriction [8, 9] , and left ventricular (LV) diastolic dysfunction [10] . Exercise-induced PH usually precedes resting PH; a sustained elevation of the mean PAP may ultimately lead to right ventricular (RV) failure and reduced survival rates [11, 12] . The structural and functional alterations of pulmonary vessels in patients with COPD increase the risk of developing symptomatic PH due to excessive hypoxic pulmonary vasoconstriction when traveling to altitude.
To date, the changes in cardiac function in lowlanders with COPD traveling to altitude are still incompletely understood. Therefore, the objective of our study was to perform a detailed echocardiographic and clinical investigation to quantify right and left heart function and hemodynamics in lowlanders with COPD traveling to high altitude.
We hypothesized that PAP would significantly increase and cardiac function deteriorate during exposure to even mild hypobaric hypoxia, similar to what is encountered by many tourists traveling to moderate altitude or by commercial air flight passengers exposed to an altitude equivalent up to 8,000 ft (2,437 m).
Methods

Study Design and Subjects
The current data were collected from participants in a randomized crossover trial evaluating the exercise performance of COPD patients traveling from 490 to 2,590 m (ClinicalTrail.gov Identifier: NCT01875133). In that study [13] , clinical characteristics, pulmonary function, and exercise tests were analyzed. The echocardiographic data reported here have not been published yet.
Men and women with moderate-to-severe COPD (GOLD grade 2 or 3) in stable condition living < 800 m and aged 18-75 years were included in this study. Patients were excluded if the following criteria were met: hypoxemia at 490 m (PaO 2 < 7.3 kPa); unstable condition; COPD exacerbation; uncontrolled cardiovascular disease; use of drugs that affect respiratory center drive; known obstructive sleep apnea syndrome; any other pulmonary disease; internal, neurologic, or psychiatric disease that interferes with protocol compliance, including current heavy smoking (> 20 cigarettes per day); previous intolerance to high altitude (< 2,600 m); or pregnancy.
Interventions
The patients underwent clinical and echocardiographic assessments at the University Hospital Zurich (490 m, low altitude; baseline) and at the Hotel Davos Jakobshorn, Switzerland (2,590 m) in the afternoon after spending 1 night at altitude. Transfers between locations were made by train and cable car within 2-5 h. The altitude exposure sequence was randomized according to a crossover design and a washout phase between examinations of > 2 weeks at 490 m.
Assessments
Patients' medical history was obtained, a clinical examination was performed, and the patients' vital parameters were measured at each altitude. Lung function testing including diffusion capacity was conducted (Bodystik TM and Diffustik TM ; Geratherm Respiratory GmbH, Bad Kissingen, Germany). Six-minute walking distance was measured according to the guidelines of the American Thoracic Society [14] .
Echocardiography
Doppler echocardiographic recordings were obtained with a real-time, phased array sector scanner (CX50 echocardiography unit with S5-1 transducer; Philips, Zofingen, Switzerland) according to guidelines of the European Association of Echocardiography [15] [16] [17] . The transtricuspid pressure gradient (TPG) was estimated from the tricuspid regurgitation peak systolic flow velocity obtained with CW Doppler using the modified Bernoulli equation: ΔP = 4 × V max 2 . Right atrial pressure (RAP) was estimated by the respiratory variability in the diameter of the inferior vena cava. The systolic PAP (sPAP) was calculated as the summation of TPG and RAP [17] . Areas of the right atrium and RV were manually traced, and the RV fractional area change (FAC) was calculated. Tricuspid annular plane systolic excursion (TAPSE) was measured by Mmode. The tissue Doppler systolic peak velocity of the RV free wall was assessed. The mean PAP was estimated from the acceleration time (AT) measured with PW Doppler in the RV outflow tract, as described by Kitabatake et al. [18] . To account for the influence of heart rate on AT, it was divided by heart rate.
The pulmonary artery wedge pressure (PAWP) was calculated using the Nagueh formula: PAWP = 1.24 × (E/e′) + 1.9 [19] . Diastolic function was graded according to the 2009 EAE/ASE Recommendations using septal e′, lateral e′, left atrial (LA) volume index, and E/A ratio. We considered septal e′ ≥8, lateral e′ ≥10, and LA volume index < 34 mL/m 2 to signify normal diastolic function; if those thresholds were not met, diastolic dysfunction was considered and further assessed by E/A ratio and average E/e′ [20] .
The imaging sequences were stored and double-checked by an independent echocardiographer (M.L.) blinded to the location. In case of relevant discrepancies in measurements, images were discussed among the echocardiographers -still blinded to location -and chosen upon agreement. 
Data Analysis and Statistics
Data analysis and statistics were performed with SPSS version 22; for regression analysis, STATA version 15 was used. The analysis was performed according to the per protocol principle on participants with data from both study locations. The data are summarized as median (lower and upper quartile) or n (%). Effects of altitude were evaluated by Wilcoxon matched-pair tests or χ 2 test and by computing mean differences with 95% CI.
Linear regression analysis was used to assess the potential effects of various baseline characteristics on the TPG at altitude. A probability of p < 0.05 was considered statistically significant.
Results
Of 191 screened patients, 151 could not be included for various reasons; 40 fulfilled the inclusion criteria and were randomized, but 3 patients withdrew their consent during the study (Fig. 1) . Data about 37 patients were available for the per protocol analysis. Their characteristics are presented in Table 1 . Their median age (quartiles) was 66 years (60; 69), 54% of the participants were male, the body mass index was 28.1 (22.1; 30.2), the median FEV 1 was 57% predicted (49; 71), and FEV 1 /FVC was 51% (42; 60). Comorbidities included arterial hypertension in 62% and stable cardiovascular diseases in 23% of the patients.
The evaluation at 2,590 m, after the patients had spent 1 night at 2,590 m, revealed a significant decrease in PaO 2 from 9.0 kPa (8.4; 9.4) to 6.6 kPa (6.3; 7.2) along with a reduced SaO 2 from 94% (93; 95) to 87% (84; 91) (both p < 0.001). This was generally well tolerated. None of the patients had to descend to lower altitude for symptomatic altitude-related disease; however, 5 patients required supplemental oxygen therapy during the night because of severe nocturnal hypoxemia (defined as SpO 2 < 80% for ≥30 min). 
Right Heart Function and Morphology
The pulmonary hemodynamics and RV function are shown in Table 2 (Fig. 2, 3) . At low altitude, 6 patients had a TRV > 2.8 m/s, and at high altitude this was the case for 18 patients. The RV outflow tract AT increased with altitude, even when indexed for heart rate (Table 2) ; correspondingly, the mean PAP increased from 19 mm Hg (16; 20) to 28 mm Hg (22; 37) (p = 0.0001). The RV end-systolic area increased, while the RV enddiastolic area remained unchanged, resulting in a reduced RV FAC and an increase in RAP. The RV wall thickness, RV/LV ratio, eccentricity indices, septal motion, TAPSE, and tissue Doppler RV systolic excursion velocity s′ remained unchanged.
Left Heart Function and Morphology
All participants had normal LV systolic function at 490 m. With ascent from 490 to 2,590 m, there was a significant increase in heart rate and a slight increase in systemic systolic blood pressure, a small increase in aortic root diameter, and a minor reduction of the LV ejection fraction (LVEF) ( Table 3 ). The mitral E/A ratio, septal mitral annulus e′ wave, and average mitral annulus e′, as well as the septal E/e′ ratio and the lateral and septal e′/a′ ratio, remained unchanged. The percentage of subjects with diastolic dysfunction, which was assessed individually according to the 2009 EAE/ASE guidelines [20] , doubled with ascent to 2,590 m (from 24 to 54%, p = 0.012). No significant change in LA dimensions and in PAWP occurred (Table 3) .
Correlation and Regression Analysis
Multivariate linear regression analysis revealed a weak correlation between baseline TPG and TPG at altitude (Table 4) . No other relevant associations between potential clinical characteristics and right or left heart parameters were found in univariate analysis.
Discussion
To our knowledge, the current study is the first comprehensive clinical and echocardiographic evaluation of lowlanders with moderate-to-severe COPD at 2,590 m. The main findings on the day after arrival at the higher altitude consisted of a moderate increase in heart rate and PAP associated with a reduced RV FAC and an increase in RAP. In addition, there was an increase in systemic systolic blood pressure, a minor reduction in LVEF, and an increase in the prevalence of diastolic dysfunction by more than half from 24 to 54% of the participants. These novel findings suggest that the hypoxemia experienced by COPD patients going to an altitude as encountered in many tourist destinations or during commercial air travel is causing considerable impairment of the pulmonary and systemic circulation that may possibly contribute to exercise limitation or even predispose to cardiac failure. In the literature, many previous studies observing effects of acute exposure to hypobaric or normobaric hypoxia have described increases in PAP in healthy subjects: Kriemler et al. [21] performed an echocardiographic field study on 20 healthy individuals (mean age 44 years) and revealed an increase in mean sPAP from 24 mm Hg at 450 m to 32 mm Hg on the first day at 3,450 m. Similar results from younger study collectives have been reported by several other authors describing sPAP values ranging from 30 ± 6 mm Hg at 3,730 m to 41 ± 3 mm Hg at 5,000 m [22] [23] [24] [25] [26] [27] [28] . Thus, with an estimated sPAP of 28 mm Hg (24; 35) at 490 m, the current COPD patients already started with higher pressures at low altitude when compared to healthy subjects, and furthermore showed a greater increase when ascending to 2,590 m; such values were reported for healthy subjects only at very high altitudes (> 4,500 m) [22] [23] [24] [25] [26] [27] .
Even though our COPD patients had values corresponding to those in healthy subjects at very high altitude, they tolerated the exposure to this altitude well, which might be explained by an as yet unknown RV adaptation to hypoxia caused by their underlying pulmonary disease [29] . The higher PAP in COPD patients is most likely due to both restriction of the pulmonary vascular bed due to parenchymal destruction of the lung and a greater degree of hypoxemia with excessive hypoxic pulmonary vasoconstriction. We did not find any significant increase in breath rate or dynamic hyperinflation with altitude in the present COPD cohort [30] , and changes in functional residual capacity and the TPG were not correlated. Thus, we do not think that any changes in respiratory mechanics contributed to the increase in PAP in these patients.
In the present study, we did not assess stroke volume and cardiac output, and thus we cannot address potential changes in pulmonary vascular resistance with altitude, which should be included in future research. The higher age of the COPD patients and their impaired LV diastolic function may additionally have contributed. However, only a minority (16%) of the COPD patients in our cohort had a TPG velocity > 2.8 m/s, as suggestive of potential PH group 3 in Zürich (460 m), but none had signs of right heart failure.
In the current COPD collective, we found a slightly increased RV end-systolic area and a slightly lower RV FAC at altitude, suggesting mild impairment of RV function probably due to an elevated afterload caused by the increased PAP. These results are in accordance with data published by Güvenç et al. [31] describing larger enddiastolic and end-systolic RV diameters and end-systolic areas as well as reduced FAC in patients with COPD liv- ing at moderate altitude. As in our study collective, Gü-venç et al. [31] could not detect any difference in TAPSE when comparing patients with COPD living at sea level with those living at moderate altitude, which might indicate that impairments of RV function are only mild, mainly driven by an increased volume and an only minor reduction in contractility.
The expected increase in heart rate and systemic blood pressure, as known from sojourns to altitude in healthy subjects due to chemoreceptor activation [32] , could likewise be observed in this COPD cohort. The systolic LVEF was slightly but significantly reduced at 2,590 m -albeit with a median decrease of only 5%, which should be interpreted with caution, since it could be within the range of measurement variability [33] . In contrast, recent studies have reported an increase in EF with acute exposure to 3,700 m [34] (n = 139) and 3,750 m (n = 15) in healthy subjects [28] . Thus, the measured reduction in EF in our COPD collective seems to be noteworthy. In addition, diastolic dysfunction seemed to increase with exposure to higher altitude. On PW tissue Doppler imaging of the mitral annulus, especially the septal E/e′ ratio increased with altitude, which may suggest a slightly increased LV filling pressure, even though the estimated PAWP and indexed LA volume were unchanged. In healthy individuals, previous studies have shown significant changes in E/A ratio during sojourns to high altitude [25, 28, 35, 36] . Gibbs [37] postulated that impaired diastolic LV filling at altitude is a consequence of an RV pressure overload causing impaired RV function, a reduction of the stroke volume, and thus venous return to the LA. However, Bernheim et al. [38] could not detect any correlation between LV diastolic dysfunction and acute changes in PAP due to exercise and exposure to high altitude in healthy subjects. It remains unclear if increases in PAP may be attributed to diastolic dysfunction or vice versa. The previously mentioned study by Güvenç et al. [31] found no significant difference in mitral E or A wave between patients with COPD living at sea level and those living at moderate altitude (1,768 m) . A partial influence of impaired LV diastolic function on increases in PAP cannot be completely dismissed, even though an association was not found in our regression analysis. It remains unclear whether LV systolic and diastolic dysfunction at altitude can be attributed to underlying cardiovascular diseases or whether it is the cause or the consequence of the increased PAP. In this COPD collective with prevalent comorbidities, it is conceivable that coronary heart disease and systemic arterial hypertension contributed to LV dysfunction during the exposure to altitude in some of the patients, but further studies are needed to clarify these assumptions. Whether the increase in PAP and the deterioration in RV function in lowlanders with COPD is sustained during prolonged exposure to altitude and associated with clinically relevant altitude-related adverse health effects, or whether acclimatization will improve the acute deterioration, is not known. Güvenç et al. [31] have shown a significantly higher PAP in high-altitude residents with COPD, and additionally it has been shown that COPD is associated with higher mortality among inhabitants of higher altitudes compared to lowlanders; however, the underlying mechanism is not yet understood [5, 6] . It might be postulated that the impairment of pulmonary vascular and RV function is one possible explanation.
Limitations
The accuracy of echocardiography in assessing cardiac function depends on acoustic windows; thus, it can be difficult to acquire data of sufficient quality from patients with COPD and emphysema. In our cohort, the echo quality was sufficient to assess predefined parameters in the vast majority of patients, i.e., the TPG could be estimated in 32 (low altitude) and 35 (high altitude) of the 37 participants. Estimates of sPAP, although highly reliable [39] , can be under-or overestimated when tricuspid regurgitation is minimal, and thus right heart catheterization would be the investigation of choice; however, this procedure was not feasible for this patient population due to its invasive nature and logistic constraints. The randomized crossover design and blinded double check of stored echocardiographic images were used to limit measurement and sequence biases to the greatest possible extent.
In all, 139 COPD patients from different pulmonology ambulatories throughout Switzerland contacted via telephone refused to participate in this study, mainly due to logistical reasons (subjectively long travel distances and no time to spend 2 nights at altitude and 1 in Zurich). A possible bias can neither be excluded nor derived from those refusals. Furthermore, only patients with COPD GOLD grade 2 or 3 with preserved functional capacity and mild hypoxemia were accepted into the study; therefore, we are not able to comment on any pulmonary vascular changes and the cardiac function of patients with very severe COPD and worse functional capacities, and at higher altitudes than 2,590 m.
Conclusion
This is the first study assessing pulmonary hemodynamics along with RV and LV function in lowlanders with COPD GOLD grade 2 or 3 after 1 night at an altitude For all independent variables, baseline measurements at 490 m were included into the analysis. R 2 = 0.315 and p = 0.07 for multivariate regression. TPG, transtricuspid pressure gradient; BMI, body mass index; SpO 2 , oxygen saturation; 6MWD, 6-min walking distance; DLCO (Hb), diffusing capacity for carbon monoxide (adjusted for hemoglobin); aHTN, arterial hypertension; CVD, cardiovascular disease; PaO 2 , oxygen partial pressure in arterial blood. of 2,590 m. Hypobaric hypoxia was associated with an increase in PAP comparable to that reported for healthy subjects at much higher altitude, i.e., > 4,500 m. Moreover, the COPD patients, some of them with treated hypertension and/or stable cardiovascular disease, displayed an increase in systemic systolic blood pressure, a very slight reduction in LVEF, and potential signs of diastolic dysfunction. Despite these cardiovascular impairments, the patients tolerated the exposure to altitude well, and none of the participants had to descend to lower altitude due to symptomatic altitude-related disease.
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